These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 15124676

  • 1. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A.
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate.
    Baker DE.
    Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
    [Abstract] [Full Text] [Related]

  • 3. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun 11; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract] [Full Text] [Related]

  • 4. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA, Verweij J.
    Expert Rev Anticancer Ther; 2003 Dec 11; 3(6):757-66. PubMed ID: 14686698
    [Abstract] [Full Text] [Related]

  • 5. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
    Joensuu H.
    Med Klin (Munich); 2002 Jan 15; 97 Suppl 1():28-30. PubMed ID: 11831069
    [Abstract] [Full Text] [Related]

  • 6. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
    Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E.
    Leuk Res; 2010 Jun 15; 34(6):827-9. PubMed ID: 19963273
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Imatinib alone and in combination for chronic myeloid leukemia.
    Druker BJ.
    Semin Hematol; 2003 Jan 15; 40(1):50-8. PubMed ID: 12563611
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate--a new oral targeted therapy.
    Savage DG, Antman KH.
    N Engl J Med; 2002 Feb 28; 346(9):683-93. PubMed ID: 11870247
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 28; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 17. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E, Judson I.
    Arch Toxicol; 2012 Jan 28; 86(1):1-12. PubMed ID: 21717109
    [Abstract] [Full Text] [Related]

  • 18. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V, Vakalopoulou S, Tziomalos K.
    Oncologist; 2005 Jan 28; 10(6):457-8. PubMed ID: 15967839
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.